Torres-Lobatón A, Lara-Gutiérrez C, Torres-Rojo A, Román-Bassaure E, Oliva PJC, Morales-Palomares MÁ, Hernández-Aten D, Morgan-Ortiz F

Language: Spanish
References: 12
Page: 598-604
PDF size: 312.91 Kb.

ABSTRACT

Background: Pelvic exenteration offers the last chance of cure for some patients with cervical cancer recurrent after radiation therapy.
Objective: To analyze factors associated with recurrence and survival after pelvic exenterations, based on a 40 years institutional experience.
Material and method: Retrospective, logitudinal and closed study from files of patients who survived to exenterative procedures at Oncology Department at the Hospital General de México, from January 1966 to December 2006, were screened in order to know risk factors predicting recurrence and survival in a follow up for at least three years.
Results: Prognostic factors in 161 patients eligible for this analysis were: diagnosis of recurrence prior 1 year 44/96 (45.8%) vs. 27/41 (65.8%) diagnosis after this time (p = 0.03), central recurrences 32/38 (84.2%) vs. 14/49 (28.5%) infiltration of lateral wall of the pelvis (0.0001), patients with 35 years old or less had a better prognosis when compared with the others: 23/33 (69%) vs. 60/128 (46%), (0.01); Infiltration of urinary bladder and or rectal wall 30/75 (40%) vs. 53/86 (61%) absence of these (0.006), tumor involving myometrium with or without adnexal metastases 6/25 (24%) vs. 77/136 (56%) absence of these reports (0.002), presence of three or more positive lymph nodes 5/16 (31%) vs. 56/90 (62%) absence of lymph nodes metastasis (0.02) and findings of hydronephrosis 2/15 (13.3%) vs. 13/19 (68.4%) of normal reports (0.01).
Conclusions: Better evolution in this series was for patients who had central recurrences.

REFERENCES

1. Hughes HS, Steller MA. Radical gynecologic surgery for cancer. Surg Oncol Clin N Am 2005;14:607-631.

2. Eifel JP, Berek SJ, Markman AM. Cancer of the cervix. In: De Vita TV, et al. Cancer. Principles and practice of oncology. Philadelphia: Lippincot-Raven. 7th ed. 2005;p:1305-1306.

3. Cáncer cervicouterino. Salud Pub Mex 2004;p:34-35.

4. Lopez JM, Spratt SJ. Exentereative pelvic surgery. J Surg Oncol 1999;72:102-114.

5. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, et al. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989;73:1027-1034.

6. Fleisch MC, Panke P, Beckmann MW, Schnuerch HG, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 2007;95:476-484.

7. Sharma S, Odunsi K, Driscoll D, Lele S. Pelvic exenterations for gynecological malignancies twenty-year experience at Roswell Park Cancer Institute. Int J Gynecol Cancer 2005;15:475-482.

8. Park JY, Choi HJ, Jeong SY, Chung J, et al. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival. J Surg Oncol 2007;96:560-568.

9. Maggioni A, Roviglione G, Landoni F, Zanagnolo V, et al. Pelvic exenteration: Ten years experience at the European Institute of Oncology in Milan. Gynecol Oncol 2009;114:64-68.

10. Marnitz S, Kohler Ch, Müller M, Behrens K, et al. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 2006;103:1023-1039.

11. Torres LA, Lara GC, Román BE, Oliva PJC y col. Cáncer cervicouterino persistente o recurrente a radiación. Experiencia con 126 exenteraciones pélvicas. GAMO 2009;8:159-165.

12. Ungar L, Palfalvi L, Novak Z. Primary pelvis exenteration in cervical cancer patients. Gynecol Oncol 2008;111:S9-S12.